Perleux^® body – Rejuvenating mesogel

Hyaluronic acid in Perleux^® body is a polysaccharide and its primary function is maintaining the correct tissue hydration, thanks to its intrinsic capacity to bind large amounts of water. The viscoelastic and hydrating properties of HA, combined with the ability to maintain an adequate level of water in the cutaneous tissues, rehydrate the skin. HA also plays a role inside the extracellular matrix, creating the physiological conditions for the proliferation, migration, and organization of the dermal cellular components. Therefore, it increases collagen production as well. Moreover, Perleux^® Body injection delivers an optimal amount of HA directly to the treated tissue to counteract the cytotoxic effects of free radicals on fibroblasts and the underlying adipose compartments.

Perleux^® body consists of 48 mg (H-HA) + 48 mg (L-HA)/ 3 mL physiological buffer solution.

Perleux^® body acts through a corrective action of natural and induced cutaneous depressions, which intervenes:

• In the physiological process of skin aging that leads to reduced skin hydration, alterations in the elastic fibers and collagen of the dermis, and a loss of turgor and skin tone.
• In the dermal tissue repair process, in case of scars resulting from superficial cutaneous trauma (e.g., acne and chicken pox scars).

Identification of 10 points on 3 horizontal levels (3-4-3 injection points) in areas of the inner side of the upper arm, abdomen and areas affected by sagging skin (such as inner thighs)
Inject 0.3 mL of product with the bolus technique in the deep dermis/subcutaneous level.

An initial cycle of two treatment sessions at 30 days intervals is recommended, followed, if necessary, by maintenance treatments every 2 months. However, it is suggested to evaluate the specific protocol according to patients’ degree of aging.

One pre-filled syringe with 1 needle 30G x ½”, in the following available volume:
3 mL pre-filled syringe – 48 mg (H-HA) + 48 mg (L-HA) of hyaluronic acid sodium salt

• The slow release of L-HA from the HA hybrid complexes does not trigger the first inflammatory cytokines, making it biocompatible.
• H-HA in Perleux^® body provides a stable HA architecture in the dermis. It gives a lifting effect.
• An increase in the expression levels of type I and type III collagen in fibroblasts, and type IV and type VII collagen in keratinocytes.
• Skin quality and hydration are both improved in the dermis and epidermis.
• Increased production of endogenous HA and elastin gives the skin a more youthful look.

• Store the product at 2-25°C.
• The content is fragile.
• Shelf life is 2 years, correctly preserved.

• The point of injection must be on healthy skin.
• Do not inject into inflamed areas.
• Avoid injection into areas with a permanent implant
• Do not inject intravenously into muscles, tendons, or mammary augmentation.
• It is not recommended for patients with acute rheumatic fever.
• It is not recommended for patients with allergic complications and anaphylactic shock.
• Avoid using Perleux^® body for patients with untreated epilepsy, patients prone to hypertrophic ulcers, patients with a history of sensitivity to hyaluronic acid and/or proteins in gram-positive bacteria (streptococci), and patients with porphyria.
• Avoid injecting Perleux^® body in pregnant or lactating women.
• Avoid injecting Perleux^® body in children.
• It must not be used in conjunction with treatments such as laser resurfacing and medium-deep skin peeling.
• Inform the patients to avoid ultraviolet exposure (protect the treated area with total sun-block creams), exposure to very low/very high temperatures, sauna, and hot baths within two weeks after the injection.
• Advise patients to discontinue aspirin, NSAIDs, anticoagulants, platelet aggregation inhibitors, and any agents that may increase bleeding risk—including herbal supplements like garlic and maidenhair—at least one week before the injection.